Medicare patients waiting days or weeks for drug plan approvals could see that timeline shrink to hours. The Centers for Medicare & Medicaid Services (CMS) has proposed rule CMS-0062-P, which would force Medicare drug plans to issue standard prior authorization decisions within 72 hours and urgent decisions within 24 hours. Public comments on the proposal close June 15, 2026, giving plans, providers, and patients just weeks to weigh in before CMS moves toward a final rule.
Why the 72-hour and 24-hour drug approval deadlines matter right now
The proposed deadlines would apply to Medicare Advantage prescription drug plans, standalone Part D plans, Medicaid managed care organizations, and CHIP plans. For patients, the change is direct: a prior authorization request that might currently sit in a queue for days would need a yes-or-no answer within 72 hours for standard cases and 24 hours when a prescriber flags the case as urgent.
CMS is not starting from scratch. A separate final rule, CMS-0057-F, already established similar decision-time requirements and API obligations for non-drug items and services, with those duties beginning in 2026. The new drug-specific proposal extends that framework to prescription medications, which account for a large share of prior authorization volume across Medicare plans.
Plans that built electronic prior authorization systems to comply with the earlier non-drug rule are better positioned to absorb the new drug deadlines without major new spending. Smaller plans that have not yet adopted those systems face a different calculus. Meeting a 24-hour turnaround on urgent drug requests requires automated intake, real-time formulary checks, and staff available around the clock. Plans still relying on fax-based workflows will need to overhaul operations before any compliance date takes effect.
CMS emphasizes that faster decisions are meant to reduce delays in treatment, particularly for beneficiaries with chronic or life-threatening conditions whose therapies can be interrupted by administrative bottlenecks. By imposing firm clocks on plan responses, the agency is signaling that extended review cycles and opaque status updates are no longer acceptable features of Medicare drug coverage.
FHIR-based APIs and the technical requirements in CMS-0062-P
Speed alone does not satisfy the proposal. CMS also requires plans to process prior authorization requests through FHIR-based application programming interfaces, the same technical standard already mandated for non-drug services. The agency’s technical guidance specifies which implementation guides payers must follow and under what conditions updated versions can be adopted.
The API requirement is designed to replace phone calls, faxes, and portal logins with a single electronic channel that connects prescriber systems directly to plan adjudication engines. When that connection works, a provider’s electronic health record can submit a prior authorization request and receive a decision without anyone picking up a phone. CMS frames this as both a speed measure and a transparency measure, because the same APIs can return the specific clinical criteria a plan used to approve or deny a request.
For providers, the practical benefit is fewer hours spent on paperwork per patient. For plans, the cost depends on how far their current technology sits from the FHIR standard. Organizations that invested early in interoperability infrastructure during the non-drug rulemaking cycle may be able to extend existing APIs to cover prescription benefits. Others will have to procure new vendor solutions, reconfigure legacy pharmacy benefit systems, and train staff on the new workflows.
CMS’s broader interoperability strategy is laid out in its policy materials for CMS-0062-P, which link the drug prior authorization changes to a multi-year effort to reduce administrative burden. The agency argues that standardized APIs can simultaneously speed up coverage decisions, make benefit rules more visible to clinicians, and give patients clearer information about why a drug was approved, denied, or redirected to an alternative.
Transparency, patient impact, and plan operations
Beyond raw turnaround times, the proposal would require plans to send more structured information back to prescribers and, in some cases, to patients. That includes explicit reasons for denials and references to coverage rules used in the decision. CMS contends that this level of detail will make it easier for clinicians to adjust prescriptions, appeal decisions, or document medical necessity without repeated back-and-forth.
Operationally, plans will have to reconcile these new expectations with existing utilization management strategies. Some may tighten internal review protocols to ensure that any denial issued within 24 or 72 hours can withstand scrutiny and potential appeals. Others may shift certain drugs out of prior authorization entirely if the administrative cost of rapid review outweighs the savings from utilization controls.
CMS underscores in its proposal announcement that the reforms are intended to speed access to medically necessary drugs while maintaining tools to manage inappropriate or unsafe prescribing. How plans balance those goals will be a central theme in public comments, especially from provider groups that have long criticized prior authorization as a barrier to care.
As the June 15, 2026, comment deadline approaches, stakeholders are parsing not only the timelines and technical standards but also the practical realities of implementation. Patients and advocacy groups are likely to support faster decisions and clearer explanations. Plans will focus on the cost and feasibility of 24-hour review for urgent cases, particularly across weekends and holidays. Providers, meanwhile, will be watching closely to see whether the promised reduction in administrative burden materializes once the new APIs and decision clocks are in place.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
